News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Nov 13, 2019

    SAN DIEGO, November 13, 2019 — Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial...

  • Nov 7, 2019
    Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo® | Announced partnership with Arcellx to develop SparX proteins used in cell therapies | Jazz advances PF743 (JZP-458) to pivotal Phase 2/3 Study expected to be initiated later this year; Jazz also announced FDA fast track designation for JZP-458, for the treatment of ALL/LBL | Earned $13.5 million in development and regulatory milestone payments

    SAN DIEGO, November 7, 2019 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...

  • Nov 6, 2019

    Conference: Jefferies 2019 London Healthcare Conference Date: Wednesday, November 20, 2019 Time: 4:00 p.m. GMT (8:00 a.m. PST) Webcast: Interested parties can access the live audio webcast and...

  • Oct 24, 2019

    SAN DIEGO, October 24, 2019-- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve...

  • Oct 14, 2019
    Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks | Pfenex believes the study report completes the information package required by the FDA to evaluate the FDA-approved PF708 product for therapeutic equivalence

    SAN DIEGO, October 14, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study...

Show 5102550100 per page
Subscribe to our Investor Alerts
* Required Fields